Tranilast attenuates TGF-β1-induced epithelial-mesenchymal transition in the NRK-52E cells

Sha-sha Li1, Qi-feng Liu2, Ao-lin He1

  • 1The Centre Laboratory, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu, China.

Insights

Tranilast directly inhibits epithelial-mesenchymal transition (EMT) by reversing transforming growth factor-beta 1 (TGF-β1) induced cellular changes. This suggests targeting EMT could prevent kidney fibrosis.

Area of Science:

  • Nephrology
  • Cell Biology
  • Pharmacology

Background:

  • Chronic cyclosporine nephrotoxicity involves the transforming growth factor-beta (TGF-β)/Smad pathway and epithelial-mesenchymal transition (EMT).
  • The precise cellular mechanisms by which tranilast halts this pathogenesis remain unclear.

Purpose of the Study:

  • To investigate the in vitro effect of tranilast on TGF-β1-induced EMT in normal rat kidney proximal tubular epithelial cells (NRK-52E).
  • To elucidate the cellular mechanisms underlying tranilast's potential to modify EMT.

Main Methods:

  • NRK-52E cells were treated with TGF-β1 alone or in combination with varying concentrations of tranilast.
  • Cell morphology was observed for EMT confirmation.
  • Western blotting and flow cytometry were used to assess E-cadherin and α-smooth muscle actin (α-SMA) protein expression.

Main Results:

  • TGF-β1 induced EMT, characterized by morphological changes, decreased E-cadherin, and increased α-SMA.
  • Tranilast reversed these TGF-β1-induced changes in a concentration-dependent manner.
  • Tranilast directly inhibited EMT in NRK-52E cells.

Conclusions:

  • Tranilast directly inhibits TGF-β1-induced epithelial-mesenchymal transition in kidney proximal tubular epithelial cells.
  • Targeting EMT represents a potential therapeutic strategy for preventing renal tubulointerstitial fibrosis.